XT
TRVI icon

XTX Topco’s Trevi Therapeutics TRVI Stock Holding History

XTX Topco’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15M Buy
61,896
+37,161
+150% +$540K 0.01% 1666
2026
Q1 		$295K Sell
24,735
-59,083
-70% -$661K 0.01% 2494
2025
Q4 		$1.05M Buy
+83,818
New +$969K 0.03% 994
2025
Q3 		– Sell
-64,589
Closed -$353K – 3293
2025
Q2 		$353K Buy
64,589
+54,209
+522% +$337K 0.01% 1323
2025
Q1 		$65.3K Sell
10,380
-56,821
-85% -$271K ﹤0.01% 1950
2024
Q4 		$277K Buy
+67,201
New +$215K 0.02% 1295

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

XTX Topco's TRVI Position: Q2 2026 in Review

XTX Topco increased its Trevi Therapeutics (TRVI) stake by 150% in Q2 2026, buying an estimated $540K and bringing the position to 61,896 shares worth $1.15M. The position accounts for 0.01% of the portfolio, ranked #1666.

XTX Topco first reported a position in TRVI in Q4 2024 and has held it in 6 quarters since. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • XTX Topco held 61,896 shares of Trevi Therapeutics worth $1.15M as of Q2 2026.
  • XTX Topco bought 37,161 Trevi Therapeutics shares in Q2 2026, an estimated $540K.
  • Trevi Therapeutics made up 0.01% of XTX Topco's portfolio in Q2 2026, its #1666 holding.
  • XTX Topco first reported a position in Trevi Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.